{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:14:43Z","timestamp":1783599283974,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"SRM Institute of Science & Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-05033-x","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:23:53Z","timestamp":1780410233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported health utility in adults with myasthenia gravis: a systematic review and meta-analysis of EQ-5D outcomes"],"prefix":"10.1186","volume":"26","author":[{"given":"Venkata Siva Karthik","family":"Budumuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshaya Kamalashree","family":"G","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariharan","family":"Murugadoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanth","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesh","family":"Basheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"5033_CR1","doi-asserted-by":"publisher","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981. https:\/\/doi.org\/10.3389\/fneur.2020.596981.","journal-title":"Front Neurol"},{"issue":"5","key":"5033_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(09)70063-8.","journal-title":"Lancet Neurol"},{"key":"5033_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/874680","volume":"2012","author":"A Jayam Trouth","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012:1\u201310. https:\/\/doi.org\/10.1155\/2012\/874680.","journal-title":"Autoimmune Dis"},{"issue":"1","key":"5033_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516. https:\/\/doi.org\/10.1186\/s12967-021-03185-7 . PubMed PMID: 34930325; PubMed Central PMCID: PMC8686543.","journal-title":"J Transl Med"},{"issue":"4","key":"5033_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/jnnp.2006.100545","volume":"78","author":"X Zhang","year":"2006","unstructured":"Zhang X, Yang M, Xu J, Zhang M, Lang B, Wang W, et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry. 2006;78(4):386\u201390. https:\/\/doi.org\/10.1136\/jnnp.2006.100545.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"5033_CR6","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","volume":"12","author":"JJGM Verschuuren","year":"2013","unstructured":"Verschuuren JJGM, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun rev. 2013;12(9):918\u201323. https:\/\/doi.org\/10.1016\/j.autrev.2013.03.001.","journal-title":"Autoimmun rev"},{"issue":"1","key":"5033_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","volume":"505","author":"D Grob","year":"1987","unstructured":"Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcomea. Annals of the New York. Acad Sci. 1987;505(1):472\u201399. https:\/\/doi.org\/10.1111\/j.1749-6632.1987.tb51317.x.","journal-title":"Acad Sci"},{"issue":"7","key":"5033_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40273-016-0389-9","volume":"34","author":"M Karimi","year":"2016","unstructured":"Karimi M, Brazier J. Health, health-related quality of life, and quality of life: what is the difference? PharmacoEconomics. 2016;34(7):645\u20139. https:\/\/doi.org\/10.1007\/s40273-016-0389-9.","journal-title":"PharmacoEconomics"},{"issue":"3","key":"5033_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40271-023-00662-7","volume":"17","author":"C Shaw","year":"2024","unstructured":"Shaw C, Longworth L, Bennett B, McEntee-Richardson L, Shaw JW. A Review of the Use of EQ-5D for clinical outcome assessment in health technology assessment, regulatory claims, and published literature. Patient. 2024;17(3):239\u201349. https:\/\/doi.org\/10.1007\/s40271-023-00662-7. PubMed PMID: 38085457; PubMed Central PMCID: PMC11039499.","journal-title":"Patient"},{"issue":"6","key":"5033_CR10","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med. 2022;11(6):1597. doi:10.3390\/jcm11061597 PubMed PMID: 35329925; PubMed Central PMCID: PMC8950430.","journal-title":"J Clin Med"},{"key":"5033_CR11","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"5033_CR12","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane Handbook for Systematic Reviews of Interventions. 1st ed. Wiley; 2019. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/book\/https:\/\/doi.org\/10.1002\/9781119536604 doi:10.1002\/9781119536604.\u00a0Cited 2026 Feb 24.","DOI":"10.1002\/9781119536604"},{"issue":"1","key":"5033_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"issue":"12","key":"5033_CR14","doi-asserted-by":"publisher","first-page":"e011458","DOI":"10.1136\/bmjopen-2016-011458","volume":"6","author":"MJ Downes","year":"2016","unstructured":"Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):e011458. https:\/\/doi.org\/10.1136\/bmjopen-2016-011458.","journal-title":"BMJ Open"},{"issue":"1","key":"5033_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/publications14010004","volume":"14","author":"E Gualdi-Russo","year":"2026","unstructured":"Gualdi-Russo E, Zaccagni L. The Newcastle\u2013Ottawa scale for assessing the quality of studies in systematic reviews. Publications. 2026;14(1):4. https:\/\/doi.org\/10.3390\/publications14010004.","journal-title":"Publications"},{"key":"5033_CR16","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"5033_CR17","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. Published 2016 Oct 12. https:\/\/doi.org\/10.1136\/bmj.i4919.","DOI":"10.1136\/bmj.i4919"},{"issue":"16","key":"5033_CR18","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/sim.4780131602","volume":"13","author":"HK Brown","year":"1994","unstructured":"Brown HK, Kempton RA. The application of REML in clinical trials. Stat Med. 1994;13(16):1601\u201317. https:\/\/doi.org\/10.1002\/sim.4780131602.","journal-title":"Stat Med"},{"issue":"1","key":"5033_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"5033_CR20","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805. https:\/\/doi.org\/10.1177\/0962280216669183.","journal-title":"Stat Methods Med Res"},{"issue":"7650","key":"5033_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"1","key":"5033_CR22","doi-asserted-by":"publisher","first-page":"e066445","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S, Beauchamp J, Chiroli S, Quinn C, et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. 2023;13(1):e066445. https:\/\/doi.org\/10.1136\/bmjopen-2022-066445.","journal-title":"BMJ Open"},{"issue":"4","key":"5033_CR23","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1007\/s12325-023-02437-w","volume":"40","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Qi CZ, Phillips G, Iannazzo S, Janssen MF. Association Between Myasthenia Gravis\u2013Activities of Daily Living (MG-ADL) and EQ-5D-5L utility values: the additional effect of efgartigimod on utilities. Adv Ther. 2023;40(4):1818\u201329. https:\/\/doi.org\/10.1007\/s12325-023-02437-w.","journal-title":"Adv Ther"},{"issue":"9","key":"5033_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.clineuro.2010.06.018","volume":"112","author":"JP Sieb","year":"2010","unstructured":"Sieb JP, K\u00f6hler W. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial. Clin Neurol Neurosurg. 2010;112(9):781\u20134. https:\/\/doi.org\/10.1016\/j.clineuro.2010.06.018.","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"5033_CR25","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1007\/s00415-021-10902-1","volume":"269","author":"LK Andersen","year":"2022","unstructured":"Andersen LK, Jakobsson AS, Revsbech KL, Vissing J. Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. J Neurol. 2022;269(6):3086\u201393. https:\/\/doi.org\/10.1007\/s00415-021-10902-1.","journal-title":"J Neurol"},{"issue":"9","key":"5033_CR26","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-010-5549-9","volume":"257","author":"Y Winter","year":"2010","unstructured":"Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schr\u00f6der R, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257(9):1473\u201381. https:\/\/doi.org\/10.1007\/s00415-010-5549-9.","journal-title":"J Neurol"},{"issue":"3","key":"5033_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3233\/JND-200484","volume":"7","author":"RHP De Meel","year":"2020","unstructured":"De Meel RHP, Barnett C, Bril V, Tannemaat MR, Verschuuren JJGM. Myasthenia gravis impairment index: sensitivity for change in generalized muscle weakness. JND. 2020;7(3):297\u2013300. https:\/\/doi.org\/10.3233\/JND-200484.","journal-title":"JND"},{"issue":"1","key":"5033_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12325-023-02704-w","volume":"41","author":"S Dewilde","year":"2024","unstructured":"Dewilde S, Phillips G, Paci S, De Ruyck F, Tollenaar NH, Janssen MF. The burden patients with myasthenia gravis experience in terms of breathing, fatigue, sleep, mental health, discomfort and usual activities in comparison to the general population. Adv Ther. 2024;41(1):271\u201391. https:\/\/doi.org\/10.1007\/s12325-023-02704-w.","journal-title":"Adv Ther"},{"issue":"3","key":"5033_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/ene.13836","volume":"26","author":"C Barnett","year":"2019","unstructured":"Barnett C, Bril V, Bayoumi AM. EQ-5D\u20105L and SF\u20106D health utility index scores in patients with myasthenia gravis. Euro J Neurol. 2019;26(3):452\u20139. https:\/\/doi.org\/10.1111\/ene.13836.","journal-title":"Euro J Neurol"},{"key":"5033_CR30","doi-asserted-by":"publisher","unstructured":"Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C. Patient-acceptable symptom states in myasthenia gravis. Neurology. 2020;95(12). https:\/\/doi.org\/10.1212\/WNL.0000000000010574.","DOI":"10.1212\/WNL.0000000000010574"},{"issue":"9","key":"5033_CR31","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s00415-025-13298-4","volume":"272","author":"M Petersson","year":"2025","unstructured":"Petersson M, Wu J, Berggren F, Schager I, Piehl F, Brauner S. Impact of disease activity on quality of life and EQ-5D-3L score in myasthenia gravis: results from the Swedish MG registry. J Neurol. 2025;272(9):562. https:\/\/doi.org\/10.1007\/s00415-025-13298-4.","journal-title":"J Neurol"},{"key":"5033_CR32","doi-asserted-by":"publisher","first-page":"1203679","DOI":"10.3389\/fneur.2023.1203679","volume":"14","author":"KJ Herr","year":"2023","unstructured":"Herr KJ, Shen SP, Liu Y, Yang CC, Tang CH. The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan. Front Neurol. 2023;14:1203679. https:\/\/doi.org\/10.3389\/fneur.2023.1203679 . PubMed PMID: 37426446; PubMed Central PMCID: PMC10327564.","journal-title":"Front Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05033-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:22:11Z","timestamp":1783596131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05033-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5033"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05033-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This systematic review and meta-analysis used data from previously published studies and did not involve direct participation of human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"450"}}